Liver/Biliary Disorders News

VANCOUVER, British Columbia — A diagnosis of and treatment for alcohol use disorder after a hospital encounter for alcohol-associated liver disease correlated with lower odds for mortality, according to a presenter here.

VANCOUVER, British Columbia — Pain was reported in nearly 80% of patients with cirrhosis evaluated for liver transplant and, when paired with anxiety and depression, was a significant driver for poor quality of life, noted a presenter here.

VANCOUVER, British Columbia — Insulin resistance, HbA1c and waist circumference represent independent risk factors for metabolic dysfunction-associated steatotic liver disease among lean patients, according to data presented here.

VANCOUVER, British Columbia — The Social Determinant Acuity Tool accurately identified patients at risk for alcohol relapse after liver transplantation for alcoholic liver disease, according to data from the ACG Annual Scientific Meeting.

DALLAS — New data presented at ObesityWeek demonstrate an encouraging early profile of an investigational dual GLP-1/GIP receptor agonist in healthy adults, according to a speaker at ObesityWeek.

Individuals with low birthweight or born small for gestational age were significantly more likely to develop nonalcoholic fatty liver disease later in life, with additionally higher odds for more severe NAFLD, according to data at UEG Week.

Liver Cancer Awareness Month, celebrated every October, seeks to raise awareness about the third deadliest cancer in the United States, with approximately 41,000 new cases and as many as 30,000 deaths each year.

Although the use of robotic-assisted cholecystectomy increased 37-fold from 2010 to 2019, the procedure was associated with significantly higher rates of bile duct injury compared with laparoscopic cholecystectomy, according to research.

Elevated serum triglyceride levels were associated with severity of acute pancreatitis and risk for related complications, including organ failure, among patients with nonalcoholic fatty liver disease, according to data.

Subcutaneous pegozafermin at weekly and biweekly doses improved fibrosis at 24 weeks vs. placebo among patients with biopsy-confirmed nonalcoholic steatohepatitis, supporting the therapy’s advancement to phase 3 development, data showed.